Price caps on non-prescription medications to be lifted starting April 2025

A presidential decree on "Additional Measures for the Accelerated Development of the Pharmaceutical Industry" has been enacted. The decree outlines new initiatives aimed at improving pharmaceutical production, updating pricing regulations, and enhancing market accessibility, with significant changes set to take effect from April 1, 2025.

Photo: KUN.UZ

The Agency for the Development of the Pharmaceutical Industry has been assigned the following additional responsibilities:

- Promoting the development of industries related to biologically active supplements and cosmetic products, including conducting market research, analyzing trends, localizing production, and supporting industry enterprises in adopting advanced foreign practices and standards;
- Collaborating with local authorities to monitor and track investment projects of regional pharmaceutical enterprises;
- Digitalizing the pharmaceutical sector and implementing information systems.

By the end of 2025, the laboratory of the Pharmaceutical Products Safety Center will undergo the World Health Organization’s initial qualification process.

The following changes will be implemented starting April 1, 2025:

- Price caps will only apply to prescription medications;
- For medications with identical compositions produced under different trade names by a single manufacturer, the lowest reference price will be applied to all such products;
- The Pharmaceutical Products Safety Center will automatically review and adjust reference prices in foreign currencies when necessary, without requiring a request from entrepreneurs.

#pharmaceuticals #pharmacy